On the basis
of the current studies as well as previous reports on the use
of intradermal immunization against influenza, hepatitis B, rabies, and other infectious diseases, 2,3,8 it is becoming clear that use
of the intradermal route may at least partially overcome the relatively poor influenza - specific immune responses seen in
certain at - risk populations, particularly the elderly, in whom the immune response in general is known to diminish with
age.9 Moreover, in times
of shortage, the dose - sparing intradermal approach might be particularly well
suited to the young, healthy
persons included in the CDC's high - priority group for vaccination, such as health care workers, as well as to younger, otherwise healthy populations in general.